Endo 17: Type 2 diabetes Flashcards

1
Q

Define DM

A

Diabetes mellitus can be defined as a state of chronic hyperglycaemia sufficient to cause long-term damage to specific tissues, notably the retina, kidney, nerves, and arteries

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

T/F T2DM is ketosis prone

A

F: not prone, but can happen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Oral glucose test

A

less than 6 when fasing

2 hrs after oral glucose, should be 7.8 or less

random test shouldn’t be above 11.1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which diabetes have greater genetic basis

A

T2DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Greatest diabetes risk

A

Greatest in ethnic groups that move from rural to urban lifestyle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pathophysiology of T2DM

A
  1. Genes and intrauterine environment and adult environment.
  2. Insulin resistance and insulin secretion defects
  3. Fatty acids important in pathogenesis and complications
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is MODY, how is it different from type 1 and type 2

A

Several hereditary forms (1-8)- i.e. MONOGENIC (so different to T2DM)

Autosomal dominant

Ineffective pancreatic B cell insulin production

+ve FH, no obesity

Due to not enough insulin production/poor insulin sensing by the b cells, NOT autoimmune destruction (like type 1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Differentiate MODY and T2DM

A

MODY monogenic, T2DM multiple genes contribute to disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What kind of mutation in MODY

A

Mutations of transcription factor genes, glucokinase gene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the relationship between intrauterine environment and T2DM

A

Intrauterine growth restriction…if you’re born light more likely to be diabetic (possible due to epigenetic mechanisms)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which factors cause macrovascular disease in T2DM

A

Genes leading to insulin resistance MODULATED (not caused by) adipocytokines. Genes can leading to obesity and FAs can affect the insulin resistance. Genes also leading to IUGR which is a risk factor for T2DM.

Insulin resistance leading to MITOGENIC (due to growth protperties of insulin) and METABOLIC DYSLIPIDAEMIA which lead to macrovascular disease.

Insulin resistance can also lead to inflammation but this doesn’t affect macrovascular disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How can you differeniate between vascular disease in diabetics vs normal people

A

Diabetics have microvascular disease, never normal people have this

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What lads to microvacular disease

A

Beta cell falure leads to metabolcic dyslipidaemia (leadingg to macrovasc)

and

HYPERGLYCAEMIA (LADS TO MICROVACULAR)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Rates of concordance in type 1 and type 2 diabetes

A

T1DM: mono= 35%, di=10%

TD2M: monozygous=70%, dizygous= 40%

DOMINANT FOR T2DM!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What else other than genetics is associated with diabetes

A

Intrauterine environment and prebirth weight

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Change in insulin prodction and resistance wih age normally

A

Increased resistace

Falling insulin production….

When it gets to a point that the resistance increases above the amount of insulin that can be produced that’s diabetes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Insulin problems in T2DM

A

Insulin resistance and insulin secretion deficit

`

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

How does insulin secretion change with impairment of glucose tolerance

A

Insulin Secretion Deteriorates with Progressive Impairment of Glucose Tolerance

The 1st phase of insulin release in response to increased glucose due to a meal is much reduced in those with impaired glucose tolerance, and not increase at all in those with TD2M.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the reason for hyperglycaemia in T2DM

A

There is inability to stop the HGO (due to insulin resistance and GLP1)

There is reduced glucose clearance (i.e. reduced ability to drive glucose into muscle and liver)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Effect of insulin resistance on adipocyte vs what happens when insulin resistance

A

Normally switches of lipolysis….

BUT if you have insulin resistance, more TG–> glycerol and NEFA….

NEFA is made into VDLD and glycerol…. glycerol turned into glucose

THIS MOSTLY COMES FROM OMENTAL FAT

See card I wrote for this bit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Effect of insulin on muslce

A

So there is more glucose produced from liver due to glycogenolysis and increased gluconeogenesis from the glycerol but

glucose cannot be taken up intomuscle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Other than the increased lipolysis, how else can adipocytes affect diabetes

A

Hormones are produced by adipocytes= adipocytokines.

E.g. TNF-a can cause lipolysis and VLDL secretion

etc.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Why is central fat more important in diabetes

A

Drains straight to liver… more endocrine function than peripheral

24
Q

Why is obesity important in diabetes

A

Fatty acids and adipocytokines important

25
Q

T/F most obese people develop diabetes

A

F- but 80% of TD2M people are obese

CENTRAL/OMENTAL obesity is most important

26
Q

Involvement of gut microbiome in T2DM

problem with most diabetes treatments, and the exception

A

It can affect intermediary metabolism

Bacterial lipopolysaccharide fermentation short chain FAs, and bacterial modulation of bile acids,

Inflammation, signaling metabolic pathways

most cause weight gain, apart from metformin

27
Q

Presentation of T2DM

Summarise the complications

A

Osmotic symptoms (less likely compared to T1DM…. so presents later, high plasma glucose leaks into urine)

Infections

On screening test

at presentation of complication

  • Acute; hyperosmolar coma,
  • Chronic; ischaemic heart disease, retinopathy

Complications:
-Macrovasc: IHD, cerebrovascular disease, renal artery stenosis, PVD

  • Microvasc: retinopathy, neuropathy and nephropathy
  • Metabolic: hyperosmolar and lactic acidosis
  • Due to treatment: hypoglycaemia
28
Q

Microvascular complicaions of diabetes

A

retinopathy
nephropathy
neuropathy

29
Q

Metabolic complicaions of diabetes

A

These are less common than in type 1

Lactic acidosis
Hyperosmolar

30
Q

Macrovascular complications of T2DM

A

Ishcaemic heart disease
Cerebrovascular
Renal artery stenosis
PVD

31
Q

Complication of treatment of diabetes

Treatment types

A

hypoglycaemia

Education, diet, pharmacological, complication screening

32
Q

How should T2DM be treated in terms of diet

A

Control total calories/increase exercise (weight)

reduce refined carbohydrate (less sugar)

increase complex carbohydrate (more rice etc)

reduce fat as proportion of calories (less IR)

increase unsaturated fat as proportion of fat (IHD)

increase soluble fibre (longer to absorb CHO)

Address salt (BP risk)

33
Q

Drugs acting on the liver to reduce sugar output

A

Metformin and insulin (but this causes weight gain

34
Q

Drugs acting on the pancrease

A

Sulphonylurease (increase insulin release)

35
Q

How does metformin work

A
insulin sensitiser
overweight patient with T2DM where diet alone has not succeeded
Reduces insulin resistance
Reduced hepatic glucose output
Increases peripheral glucose disposal
36
Q

What is measured in TD2M for monitoring

What drug works to reduce fat absorption

What drugs work on sugar

A

Weight
Glycaemia
Blood pressure
Dyslidiaemia

ORLISTAT is a GI lipase inhibitor

RIMONABANT is a cabbanoid antagonist (suppress action of GABA on the MCH neurones, and prevent increased orexin production)

Metformin/insulin (but it would cause weigt gain) reduce HGO

Sulphonylureas increase insulin secretion from pancreas (control sugar but cause weight gain)

a-glucosidase inhibitor… increasing time to absorb sugar (gets over the reduced 1st phase insulin release)

GLP1 anlogue + DPP4 inhibitor (to increase amount of insulin from pancreas)

Thiazolidinediones (deal with insulin resistance)

SGLT2 inhibitor= increase glucose excretion

37
Q

How does metformin work

When is it indicated

How does it work

Side effects and contraindication

A

Biguanide, insulin sensitiser

overweight patient with T2DM where diet alone has not succeeded

Reduces insulin resistance:
-Reduced hepatic glucose output

-Increases peripheral glucose disposal

GI side effects

Not in severe heart, liver or MILD renal failure

38
Q

Release of insulin

A

Glucose comes in, increases ATP, blocks ATP sensitive K+channels,

causes Ca2+ influx and insulin release

39
Q

When can sulphonylureas be used

A

When patient still has some beta cell function

40
Q

How does sulphylureas work and what are they also known as

A

INSULIN SECRETAGOGUES

Blocks the ATP sensitive K+ chanenel, forcing it to close to increase insulin release

USED IN TYPE II ONLY (not type I there is no pancreatic function)

cause weight gain

41
Q

What is acarbose

A

Alpha glucosidase inhibitor

Prolongs absorption of oligosaccharides

Allows insulin secretion to cope, following defective first phase insulin

As effective as metformin

42
Q

Side effects of acarbose

A

Flatus

43
Q

Actio of thiazolidineodione

A

Peroxisome proliferator-actived receptor agonists PPAR-γ

Insulin sensitizer, mainly peripheral
Adipocyte differentiation modified, weight gain but peripheral not central

Improvement in glycaemia and lipids
Evidence base on vascular outcomes

Older types cause hepatitis

44
Q

Side effects of thiazolidineodiones

A

Side effects of older types hepatitis, heart failure

45
Q

What happens if you inject someone with glucose vs get someone to drink glucose orally

A

If you inject glucos into one patient, and oral administer glucose in another, then you get MUCH more insulin secretion in oral admin.

46
Q

What is the incretin effect

A

Secreted in response to nutrients in gut

Release of hormones from L cells in GI system increase insulin secretion

47
Q

What is GLP1 made from and what is its effect

How is it broken down

A

Transcription product of proglucagon gene, mostly from L cell.

Stimulates insulin, suppresses glucagon

Increases satiety

Restores B cell glucose sensitivity

Short half life, rapid degredation from enzyme dipeptidyl peptidase-4

48
Q

Use therapeutically of GLP1

A

GLP-1 agonist .. INJECTED

AND

DPPG4 inhibitor = GLIPTINS … ORAL (but not as effective)

49
Q

Effect of GLP1 on weight

A

weight loss (due to feeling of satiety)

50
Q

GLP1 example, PK and action

A
  • Exenatide, liraglutide
  • Injected
  • Long acting GLP-1 agonist
  • Decrease glucagon
  • Decrease glucose
  • Weight LOSS
51
Q

DPPG-4 inhibitor, example, PK and action

A
GLIPTINS 
Increase half life of exogenous GLP-1
Increase [GLP-1]
Decrease [glucagon]
Decrease [glucose]
Neutral on weight
52
Q

How do SGLT2 inhibitors work

A

Reduce uptake of glucose from the PCT (block SGLT2, which is a Na/glucose transporter inhibitor) but leads to osmotic symptoms

REALLY GOOD for heart failure and also lower mortality

53
Q

Why do lots of patient s eventually need insulin

A

Because of the beta cell failure that eventually occurs

54
Q

What else should we control in T2DM

A

Blood pressure

Diabetic dyslipidaemia (reduce cholesterol, TGs and increase HDL)

55
Q

Screening for diabetes

A

Specifics of program unclear

Diagnosis on glucose, fasted or stimulated?

56
Q

How to prevent progression to diabtetes

A

Diet and exercise BETTER than metformin